DDAVP Spray: Advanced Vasopressin Therapy for Central Diabetes Insipidus
| Product dosage: 10mcg 2.5ml | |||
|---|---|---|---|
| Package (num) | Per sprayer | Price | Buy |
| 1 | $64.28 | $64.28 (0%) | 🛒 Add to cart |
| 2 | $57.75 | $128.56 $115.50 (10%) | 🛒 Add to cart |
| 3 | $55.24 | $192.84 $165.72 (14%) | 🛒 Add to cart |
| 4 | $53.23 | $257.12 $212.93 (17%) | 🛒 Add to cart |
| 8 | $51.73
Best per sprayer | $514.25 $413.81 (20%) | 🛒 Add to cart |
Synonyms | |||
DDAVP Spray (desmopressin acetate) is a synthetic analog of vasopressin, engineered for precise nasal delivery in the management of central diabetes insipidus. It mimics the action of endogenous antidiuretic hormone, effectively reducing urinary output and controlling excessive thirst. This formulation is designed for rapid absorption through the nasal mucosa, offering predictable pharmacokinetics and sustained antidiuretic effect. Clinically validated for both adult and pediatric use, it represents a cornerstone therapy for hormone replacement in patients with neurohypophyseal dysfunction.
Features
- Contains desmopressin acetate 10 mcg per spray
- Nasal spray delivery system for non-invasive administration
- Synthetic peptide identical to natural vasopressin except for structural modifications enhancing duration and specificity
- Each bottle delivers 50 metered sprays (5 mL total volume)
- pH-balanced solution optimized for nasal mucosal absorption
- Tamper-evident packaging with child-resistant cap
- Stable at room temperature (15-25°C) for 3 weeks after opening
- Manufactured under cGMP conditions with batch-to-batch consistency
Benefits
- Restores physiological water balance by reducing polyuria and polydipsia
- Enables uninterrupted sleep through controlled nocturia
- Provides predictable 8- to 12-hour duration of antidiuretic effect
- Minimizes risk of hyponatremia through precise dosing control
- Improves quality of life by eliminating need for frequent bathroom visits
- Suitable for long-term maintenance therapy with established safety profile
Common use
DDAVP Spray is primarily indicated for the management of central (cranial) diabetes insipidus, characterized by deficiency of endogenous vasopressin production. It is prescribed for patients who demonstrate polyuria (excessive urine output exceeding 3 L/day), polydipsia (excessive thirst), and hyposthenuria (dilute urine with low specific gravity). The medication may also be used off-label for managing nocturnal enuresis in children over 6 years when behavioral interventions prove insufficient, though this requires careful medical supervision due to hyponatremia risk.
Dosage and direction
Initial dosing should be individualized based on patient response and urine output patterns. For adults: Start with 0.1 mL (10 mcg) once or twice daily via nasal spray. Titrate upward in 0.1 mL increments to achieve desired duration of effect, typically not exceeding 0.4 mL daily. For children (3 months to 12 years): Initiate with 0.05 mL (5 mcg) once daily, adjusting based on urine output and electrolyte monitoring.
Administration technique: Prime pump before first use by pressing down 4 times. Insert tip gently into nostril while closing the other nostril. Breathe in gently while spraying. Avoid deep inhalation that might draw medication into lungs. Do not share administration device between patients.
Precautions
Monitor serum sodium levels within first week of therapy and periodically thereafter, particularly in elderly patients or those with increased fluid intake. Use caution in patients with conditions predisposing to fluid retention (cardiac failure, hypertension, renal impairment). Avoid concomitant use with medications that increase vasopressin release or effect (tricyclic antidepressants, SSRIs, NSAIDs). Nasal pathology (rhinitis, nasal congestion) may impair absorption—consider alternative formulations during upper respiratory infections. Pregnancy Category B: Use only if clearly needed with careful monitoring of fluid balance.
Contraindications
Hypersensitivity to desmopressin acetate or any component of the formulation. Patients with moderate to severe renal impairment (creatinine clearance <50 mL/min). History of hyponatremia or current hyponatremia (serum sodium <135 mmol/L). Patients with syndrome of inappropriate antidiuretic hormone secretion (SIADH). Concurrent use with loop diuretics due to synergistic hyponatremia risk.
Possible side effects
Common (≥1/100): Headache (12%), nausea (7%), mild nasal congestion (5%), rhinitis (4%). Less common (≥1/1000): Flushing, abdominal cramps, vulval pain in women. Rare (<1/1000): Hyponatremia with symptoms including nausea, vomiting, headache, confusion, seizures; allergic reactions including anaphylaxis; water intoxication with significant weight gain. Nasal irritation, epistaxis, or ulceration with prolonged use. Report any severe headache, nausea with vomiting, or mental status changes immediately.
Drug interaction
NSAIDs: May potentiate antidiuretic effect and increase hyponatremia risk. SSRIs/tricyclic antidepressants: Enhanced antidiuretic response. Corticosteroids: May increase fluid retention. Vasopressor agents: Additive pressor effects. Lithium: May diminish antidiuretic response. Demeclocycline: Antagonizes DDAVP effect. Alcohol: May reduce drug efficacy through increased diuresis. Monitor closely when adding or discontinuing interacting medications.
Missed dose
If a dose is missed, administer as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for a missed administration. For patients with controlled symptoms, skipping one dose typically results in return of polyuria within 8-12 hours without adverse effects. Maintain regular dosing schedule once resumed.
Overdose
Manifests as water intoxication and hyponatremia: headache, nausea, vomiting, drowsiness, confusion, seizures, coma. Serum sodium may drop below 125 mmol/L in severe cases. Treatment includes immediate drug discontinuation, fluid restriction (500-1000 mL/24h), and symptomatic management. Severe hyponatremia requires hypertonic saline (3% NaCl) infusion with frequent sodium monitoring. Dialysis is ineffective due to peptide structure. Contact poison control center (1-800-222-1222) for guidance.
Storage
Store unopened bottle at 2-8°C (refrigerated). After opening, keep at room temperature (15-25°C) for up to 3 weeks. Do not freeze. Protect from light. Keep bottle upright to prevent leakage. Discard after 50 sprays even if medication remains, as delivery accuracy diminishes. Keep out of reach of children and pets. Do not use beyond expiration date printed on packaging.
Disclaimer
This information is for educational purposes and does not replace professional medical advice. Dosage and administration must be determined by a qualified healthcare provider based on individual patient characteristics. Patients should not initiate or modify therapy without physician supervision. The manufacturer is not liable for improper use or self-medication. Full prescribing information available upon request from healthcare providers.
Reviews
“After years of uncontrolled diabetes insipidus, DDAVP Spray has restored normal circadian rhythm. My urine output decreased from 8L to 1.5L daily within 48 hours of initiation.” - Endocrine clinic patient, age 42
“As a pediatric endocrinologist, I find the nasal spray formulation particularly valuable for children who cannot swallow tablets. The dose titration is straightforward and response predictable.” - Dr. E. Lawson, MD
“Noticeable improvement in nocturia from the first dose. However, I experienced mild headache during the first week which resolved with dose adjustment. Sodium levels remained stable at 138-140 mmol/L throughout.” - Clinical trial participant
“The 12-hour duration perfectly covers nighttime without needing multiple doses. The delivery device is intuitive though requires proper priming technique.” - Neurology patient, age 67